Literature DB >> 10866661

AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor.

J Font de Mora1, M Brown.   

Abstract

Growth factor modulation of estrogen receptor (ER) activity plays an important role in both normal estrogen physiology and the pathogenesis of breast cancer. Growth factors are known to stimulate the ligand-independent activity of ER through the activation of mitogen-activated protein kinase (MAPK) and the direct phosphorylation of ER. We found that the transcriptional activity of AIB1, a ligand-dependent ER coactivator and a gene amplified preferentially in ER-positive breast cancers, is enhanced by MAPK phosphorylation. We demonstrate that AIB1 is a phosphoprotein in vivo and can be phosphorylated in vitro by MAPK. Finally, we observed that MAPK activation of AIB1 stimulates the recruitment of p300 and associated histone acetyltransferase activity. These results suggest that the ability of growth factors to modulate estrogen action may be mediated through MAPK activation of the nuclear receptor coactivator AIB1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866661      PMCID: PMC85954          DOI: 10.1128/MCB.20.14.5041-5047.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  42 in total

1.  Estrogen hits the surface.

Authors:  P Collins; C Webb
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

2.  The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons.

Authors:  C A Singer; X A Figueroa-Masot; R H Batchelor; D M Dorsa
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

3.  Molecular determinants of the estrogen receptor-coactivator interface.

Authors:  H Y Mak; S Hoare; P M Henttu; M G Parker
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

4.  Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins.

Authors:  H Ma; H Hong; S M Huang; R A Irvine; P Webb; P J Kushner; G A Coetzee; M R Stallcup
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

Review 5.  IGF-I physiology and breast cancer.

Authors:  M Pollak
Journal:  Recent Results Cancer Res       Date:  1998

6.  Regulation of transcription by a protein methyltransferase.

Authors:  D Chen; H Ma; H Hong; S S Koh; S M Huang; B T Schurter; D W Aswad; M R Stallcup
Journal:  Science       Date:  1999-06-25       Impact factor: 47.728

7.  Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators.

Authors:  M Ito; C X Yuan; S Malik; W Gu; J D Fondell; S Yamamura; Z Y Fu; X Zhang; J Qin; R G Roeder
Journal:  Mol Cell       Date:  1999-03       Impact factor: 17.970

8.  Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex.

Authors:  C Rachez; B D Lemon; Z Suldan; V Bromleigh; M Gamble; A M Näär; H Erdjument-Bromage; P Tempst; L P Freedman
Journal:  Nature       Date:  1999-04-29       Impact factor: 49.962

9.  Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1.

Authors:  A Tremblay; G B Tremblay; F Labrie; V Giguère
Journal:  Mol Cell       Date:  1999-04       Impact factor: 17.970

10.  Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen.

Authors:  Z Chen; I S Yuhanna; Z Galcheva-Gargova; R H Karas; M E Mendelsohn; P W Shaul
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

View more
  102 in total

Review 1.  Estrogen receptors: orchestrators of pleiotropic cellular responses.

Authors:  J G Moggs; G Orphanides
Journal:  EMBO Rep       Date:  2001-09       Impact factor: 8.807

2.  Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor.

Authors:  D C Márquez; J Lee; T Lin; R J Pietras
Journal:  Endocrine       Date:  2001-11       Impact factor: 3.633

3.  Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor.

Authors:  D Knutti; D Kressler; A Kralli
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 4.  Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling.

Authors:  Paul H Driggers; James H Segars
Journal:  Trends Endocrinol Metab       Date:  2002-12       Impact factor: 12.015

Review 5.  The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

Authors:  Donald P McDonnell; Suzanne E Wardell
Journal:  Curr Opin Pharmacol       Date:  2010-12       Impact factor: 5.547

Review 6.  Mechanisms of resistance to hormonal treatment in breast cancer.

Authors:  P Eroles; A Bosch; B Bermejo; A Lluch
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

Review 7.  The changing role of ER in endocrine resistance.

Authors:  Agostina Nardone; Carmine De Angelis; Meghana V Trivedi; C Kent Osborne; Rachel Schiff
Journal:  Breast       Date:  2015-08-10       Impact factor: 4.380

8.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Authors:  Gladys Morrison; Xiaoyong Fu; Martin Shea; Sarmistha Nanda; Mario Giuliano; Tao Wang; Teresa Klinowska; C Kent Osborne; Mothaffar F Rimawi; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2014-02-20       Impact factor: 4.872

Review 10.  Long-term consequences of estrogens administered in midlife on female cognitive aging.

Authors:  Jill M Daniel; Christine F Witty; Shaefali P Rodgers
Journal:  Horm Behav       Date:  2015-04-25       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.